Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Based on iTunes & Spotify (publisher stats).
- Per-Episode Audience
Est. listeners per new episode within ~30 days
10,001 - 25,000 - Monthly Reach
Unique listeners across all episodes (30 days)
25,001 - 75,000 - Active Followers
Loyal subscribers who consistently listen
15,001 - 40,000
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 11 epsHost
Recent guests
No guests detected in recent episodes.
Recent episodes
E135: IL17 and a GLP1?
Apr 30, 2026
11m 03s
E134: Brepocitinib in Dermatomyositis (VALOR)
Apr 17, 2026
14m 58s
E133: Obinutuzumab for SLE (ALLEGORY)
Mar 19, 2026
15m 21s
E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE)
Mar 5, 2026
13m 54s
E131: A Sham-Controlled Sham of a Trial: RESET-RA
Jan 21, 2026
14m 48s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 4/30/26 | E135: IL17 and a GLP1?✨ | IL17 inhibitorsGLP1 inhibitors+3 | — | ixekizumabtirzepatide+2 | — | IL17GLP1+5 | — | 11m 03s | |
| 4/17/26 | E134: Brepocitinib in Dermatomyositis (VALOR)✨ | dermatomyositisbrepocitinib+3 | — | brepocitinibautoimmunedevreport.substack.com+2 | — | brepocitinibdermatomyositis+3 | — | 14m 58s | |
| 3/19/26 | E133: Obinutuzumab for SLE (ALLEGORY)✨ | rheumatologyclinical trials+3 | — | obinutuzumabNEJM+2 | — | obinutuzumabSLE+3 | — | 15m 21s | |
| 3/5/26 | E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE)✨ | osteoporosisromosozumab+4 | — | Romosozumab vs teriparatide for osteoproosishttps://pubmed.ncbi.nlm.nih.gov/28755782/ | — | osteoporosisromosozumab+6 | — | 13m 54s | |
| 1/21/26 | E131: A Sham-Controlled Sham of a Trial: RESET-RA✨ | rheumatoid arthritisvagal nerve stimulation+3 | — | NatureRESET-RA | — | RESET-RArheumatoid arthritis+3 | — | 14m 48s | |
| 12/22/25 | E130: Telitacicept for SLE✨ | rheumatologyclinical trials+4 | — | telitaciceptFDA+3 | — | telitaciceptSLE+4 | — | 13m 06s | |
| 12/4/25 | E129: Long Term Routine Laboratory Monitoring in RA✨ | laboratory monitoringrheumatoid arthritis+3 | — | ACR Convergence 2025E129: Long Term Routine Laboratory Monitoring in RA+1 | — | rheumatoid arthritislaboratory monitoring+3 | — | 15m 17s | |
| 11/12/25 | E128: Nerandomilast for Autoimmune ILD (FIBRONEER-ILD)✨ | autoimmune diseasespulmonary fibrosis+3 | — | nerandomilastNEJM | autoimmune ILD | nerandomilastautoimmune ILD+3 | — | 19m 03s | |
| 9/22/25 | E127: TNFs and All That CHF✨ | safetyTNFs+3 | — | TNFsCHF+3 | — | TNFsCHF+4 | — | 21m 46s | |
| 9/8/25 | E126: Risk Signals, JAKs, and SELECTIVE-ity✨ | rheumatologyJAK inhibitors+4 | — | ScienceDirectORAL-SURVEILLANCE+1 | — | rheumatoid arthritisJAKs+5 | — | 14m 34s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 6/29/25 | E125: Adrenal Insufficiency after Stopping Prednisone✨ | adrenal insufficiencyprednisone+3 | — | prednisoloneJAMA Open | — | adrenal insufficiencyprednisone+3 | — | 17m 52s | |
| 6/12/25 |  e124: MTX vs Pred for Pulmonary Sarcoidosis: PREDMETH Study | Interesting NEJM trial this week comparing methotrexate to prednisone for pulmonary sarcoidosis. Paper available here: https://www.nejm.org/doi/full/10.1056/NEJMoa2501443 | 14m 18s | ||||||
| 4/30/25 | E123: Upadacitinib for Giant Cell Arteritis: SELECT-GCA | Podcast this week about the recently published SELECT-GCA study, which evaluated the use of the janus kinase inhibitor upadacitinib (Rinvoq) for patients with new and relapsing GCA. Successful trial and an interesting topic. Paper itself here: https://www.nejm.org/doi/full/10.1056/NEJMoa2413449 | 18m 13s | ||||||
| 4/17/25 | E122: Guidelines for Maybe Diagnosing HLH | This week I cover another of my newsletters, though I mostly use it as a skeleton to riff on a common (and challenging) issue for rheumatology consultants; diagnosing HLH. Check out the guidelines themselves here and have a listen to the podcast! https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00273-4/fulltext | 11m 18s | ||||||
| 4/2/25 | E121: Obinutuzumab in SLE-LN | Another day, another b cell podcast. Seems to be all the rage! This week I discuss the recently published NEJM trial of the anti CD20 agent obinutuzumab in lupus nephritis. Worth a read and listen, paper can be found here: https://www.nejm.org/doi/full/10.1056/NEJMoa2410965 | 18m 14s | ||||||
| 3/6/25 | E120: Real Life Use of PEXIVAS-Low | What do you do when observational data and RCTs conflict? This week I'm covering the "real world PEXIVAS" study that was done by the French Vasculitis Study Group. Great read, interesting issues, have a listen and be sure to share with friends! | 24m 33s | ||||||
| 2/10/25 | E119: Teclistamab for Rheumatology Writ Large | One of my rare case-report podcasts, a topic that I typically avoid. The craze about CAR-T has also made me a little crazy, though, so I wanted to share what I think may be the ultimate destination for "more B cell depletion than rituximab" strategies. Article: https://www.nejm.org/doi/full/10.1056/NEJMc2407150 | 10m 52s | ||||||
| 1/31/25 | E118: The emerging risk of overdiagnosis in RA and PMR | Podcast this week about overdiagnosis! Currently one of my favorite topics and something that I think will be an emerging issue in our field. We recently published a Viewpoint in Lancet Rheumatology (https://pubmed.ncbi.nlm.nih.gov/39341221/) addressing this issue. I'm going to read from it and after that will be giving a few final (spicy) thoughts on the topic. Hope you find it worthwhile! s | 16m 02s | ||||||
| 12/3/24 | E117: Inebilizumab for IgG4-RD (MITIGATE) | New RCT in a new disease with a new drug! But is it as shiny as one would hope? Interesting discussion today about what a trial means, how it will affect practice, and how we could do better as a field. Happy holidays everyone! | 12m 55s | ||||||
| 11/11/24 | E116: A New Paradigm for PMR | Reading one of my recent newsletters this week, this one about PMR tapers. Be sure to subscribe at ebrheum.com if you want access to the visuals and upcoming editions! | 9m 29s | ||||||
| 10/28/24 | E115: Benralizumab for EGPA - the MANDARA Study | Quick rundown of an important rheumatology RCT this week, discussing the IL-5 inhibitor benralizumab for the treatment of relapsing/refractory EGPA. MANDARA Study: https://www.nejm.org/doi/full/10.1056/NEJMoa2311155 | 9m 52s | ||||||
| 10/14/24 | E114: Target Trials and STAR-RA with Rishi Desai | Important methodology podcast this week, covering a lot of ground with expert epidemiologist Rishi Desai. Really enjoyed our conversation and glad to be publishing today! **House Keeping Note: we actually recorded this ~15 months ago but I somehow lost the audio... which somehow re-appeared! #technology STAR-RA: https://pubmed.ncbi.nlm.nih.gov/35027405/ | 31m 15s | ||||||
| 9/30/24 | E113: CAR-T is Coming to Rheumatology | Exciting podcast this week about the upcoming / impending use of CAR-T in rheumatology. Highly recommend rheumatologists learn about this now; it's going to be a big thing for many years to come. In a future episode I will lay out my case for skepticism, but for now I think a good run down of the first big published series will be enough! NEJM CAR-T Case Series: https://www.nejm.org/doi/full/10.1056/NEJMoa2308917 Nature Review Article: https://www.nature.com/articles/s41584-024-01139-z | 14m 04s | ||||||
| 9/12/24 | E112: Gabapentin is Trash | This week's podcast will be a quick read of one of my newsletters. The title basically speaks for itself! Find the newsletter and my other work at ebrheum.com | 6m 07s | ||||||
| 3/25/24 | E111: PEXIVAS Subsets with Mike Walsh & Mats Junek | At ACR23 I had a twitter-disagreement about steroid tapers from PEXIVAS with Mike Walsh, the lead author on the PEXIVAS trial. He kindly agreed to join me for a moderated discussion. Loved hearing his perspective and have to admit he pulled me closer to his practice... but not all the way there. Longer podcast than usual but I prefer to release audio uncut and this took as long as it needed! Hoping y'all enjoy. Articles referenced during the podcast: PEXIVAS: https://www.nejm.org/doi/full/10.1056/nejmoa1803537 PEXIVAS DAH Subset: https://www.atsjournals.org/doi/10.1164/rccm.202308-1426OC Fussner Abstract: https://acrabstracts.org/abstract/characteristics-and-outcomes-of-participants-with-and-without-diffuse-alveolar-hemorrhage-in-the-plasma-exchange-and-glucocorticoids-in-severe-anca-associated-vasculitis-pexivas-trial/ Walsh Meta Analysis: https://pubmed.ncbi.nlm.nih.gov/35217545/ | 39m 27s | ||||||
Showing 25 of 100
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
6 placements across 6 markets.
Chart Positions
6 placements across 6 markets.